Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib + Ziv-Aflibercept in Advanced Cancers
NCT02159989Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2014
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sapanisertib in malignant solid neoplasm, Pancreatic neuroendocrine tumor (PanNET) and ovarian carcinoma, sponsored by National Cancer Institute. Primary endpoints: Dose-limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Started Jun 2014; status: completed.
02
Drugs
sapanisertib
03
Conditions
malignant solid neoplasmPancreatic neuroendocrine tumor (PanNET)ovarian carcinoma
Beyond the preview
Go deeper on NCT02159989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159989.